Healthcare provider profile · identity verified

Sumathi Suppiah, MD

Family Practice · YORK, PA · NPI 1164679122

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	431	125
Lisinopril	Lisinopril	329	92
Levothyroxine Sodium	Levothyroxine Sodium	234	61
Amlodipine Besylate	Amlodipine Besylate	227	70
Metformin Hcl Er	Metformin Hcl	164	52
Pantoprazole Sodium	Pantoprazole Sodium	143	42
Alendronate Sodium	Alendronate Sodium	140	38
Metformin Hcl	Metformin Hcl	135	35
Losartan Potassium	Losartan Potassium	120	41
Simvastatin	Simvastatin	120	34
Omeprazole	Omeprazole	112	46
Albuterol Sulfate Hfa	Albuterol Sulfate	109	32
Gabapentin	Gabapentin	109	34
Rosuvastatin Calcium	Rosuvastatin Calcium	106	32
Fluticasone Propionate	Fluticasone Propionate	99	28
Metoprolol Succinate	Metoprolol Succinate	94	27
Hydrochlorothiazide	Hydrochlorothiazide	93	32
Metoprolol Tartrate	Metoprolol Tartrate	86	26
Trazodone Hcl	Trazodone Hcl	84	26
Ozempic	Semaglutide	78	12
Escitalopram Oxalate	Escitalopram Oxalate	70	17
Montelukast Sodium	Montelukast Sodium	70	24
Meloxicam	Meloxicam	68	24
Citalopram Hbr	Citalopram Hydrobromide	67	18
Eliquis	Apixaban	66	20
Sertraline Hcl	Sertraline Hcl	56	14
Tamsulosin Hcl	Tamsulosin Hcl	54	16
Buspirone Hcl	Buspirone Hcl	46	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	14
Jardiance	Empagliflozin	45	11
Rybelsus	Semaglutide	44	13
Bupropion Hcl Sr	Bupropion Hcl	43	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	43	13
Duloxetine Hcl	Duloxetine Hcl	42	13
Ezetimibe	Ezetimibe	41	17
Spironolactone	Spironolactone	41	suppressed
Alprazolam	Alprazolam	39	suppressed
Atenolol	Atenolol	39	11
Breo Ellipta	Fluticasone/Vilanterol	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	11
Bupropion Xl	Bupropion Hcl	36	13
Clopidogrel	Clopidogrel Bisulfate	35	suppressed
Famotidine	Famotidine	34	12
Carvedilol	Carvedilol	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Glipizide	Glipizide	33	12
Ropinirole Hcl	Ropinirole Hcl	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Potassium Chloride	Potassium Chloride	30	12
Clonazepam	Clonazepam	28	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Glipizide Er	Glipizide	26	suppressed
Furosemide	Furosemide	24	suppressed
Mounjaro	Tirzepatide	24	suppressed
Allopurinol	Allopurinol	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Incruse Ellipta	Umeclidinium Bromide	19	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Brilinta	Ticagrelor	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Pindolol	Pindolol	11	suppressed
Wegovy	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error